Skip to main content

Table 2 Percentage of patients with improved, stable, or worsened QLQ-C30 scores from baseline at cycle 6

From: Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

Symptom/Scale

Study 206

Study 208

n

Improved (%)

Stable (%)

Worsened (%)

n

Improved (%)

Stable (%)

Worsened (%)

GHS/QoL

29

6.9

55.2

37.9

44

29.5

52.3

18.2

Physical functioning

29

31.0

44.8

24.1

44

22.7

59.1

18.2

Role functioning

29

48.3

34.5

17.2

44

29.5

45.5

25.0

Emotional functioning

29

31.0

48.3

20.7

44

38.6

40.9

20.5

Cognitive functioning

29

6.9

44.8

48.3

44

13.6

40.9

45.5

Social functioning

29

34.5

44.8

20.7

44

27.3

40.9

31.8

Fatigue

29

55.2

17.2

27.6

44

31.8

18.2

50.0

Nausea and vomiting

29

27.6

55.2

17.2

44

20.5

54.5

25.0

Pain

29

51.7

27.6

20.7

44

47.7

31.8

20.5

Dyspnea

29

31.0

62.1

6.9

44

27.3

43.2

29.5

Insomnia

29

41.4

51.7

6.9

44

36.4

36.4

27.3

Appetite loss

29

24.1

55.2

20.7

44

22.7

45.5

31.8

Constipation

29

17.2

62.1

20.7

44

25.0

43.2

31.8

Diarrhea

29

6.9

72.4

20.7

44

9.1

65.9

25.0

Financial difficulties

29

13.8

69.0

17.2

44

29.5

50.0

20.5

  1. GHS global health status, QoL quality of life
  2. For global health status and functional scales, improved scores are defined as increases from baseline ≥10; worsened is defined as decreases from baseline ≥10. For symptom scales/items, improved scores are defined as decreases from baseline ≥10; worsened is defined as increases from baseline ≥10
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us